65,437 trials
Critical Illness · Communication Disabilities
Primary: Change in Peritraumatic Distress Inventory — 14.6; 14.2; 13.0; 14.4 score on a scale
Obesity · Overweight · Binge Eating
Primary: Changes in Food-cue Visual Probe Task Attention Bias (AB) Reaction Time — 1.85; 4.27 Change in milliseconds
Wrinkles in Decolletage
Primary: Percentage of Responders on the Galderma Décolletage Scale (GDS), as Assessed Live by the Treating Investigator, at Month 9 — 93.8; 78.6 percentage of Participants
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events — 19 Participants
Insomnia
Primary: Change in Sleep Efficiency as Measured by Polysomnogram — 8.9; 9.4 Percentage (see sleep efficiency def) — p=0.72
Arrhythmogenic Right Ventricular Cardiomyopathy
Primary: Number of Ventricular Ectopic Beats (VEBs) Per Day — 2685; 677 number of VEBs per day — p=<0.0001
Peripheral Artery Disease
Primary: Maximum Walking Time From the Gardner Graded Treadmill Protocol — 117.7; 197.5; 188; 339.9 Seconds
Depression, Unipolar
Primary: Montgomery-Asberg Depression Rating Scale — 12.50; 13.30 score on a scale
Platysma Prominence
Primary: Number of Participants With Adverse Events — 43; 34 Participants
Breast Adenocarcinoma · Metastatic Triple-Negative Breast Carcinoma · Stage III Breast Cancer AJCC v7
Primary: Maximum Tolerated Dose (MTD) of Pembrolizumab in Combination With Binimetinib Using the Standard 3+3 Design (Phase I) — 2; 0; 1; 6 Participants
Soft Tissue Approximation · Elevation of Subdermis · Elevation of Underlying Muscle
Primary: Physician Global Aesthetic Improvement Score (PGAIS) — 5; 3; 2; 0 Participants
Cardiovascular Risk Factor · Health Behavior · Physical Activity
Primary: Change in Mean Systolic and Diastolic Blood Pressure (mm/Hg) From Baseline (Time 1) to Time 2 — -0.3; -2.4; 1.2; 2.2 mmHg
LVAD (Left Ventricular Assist Device) Thrombosis
Primary: Evaluation of Hemocompatibility Related Adverse Events During Apixaban Use With the HeartMate 3 LVAS — 0; 1; 2 Participants
Anesthesia, Local
Primary: Percent of Sharp (as Opposed to Dull) Sensation Over Application Area — 51.6; 82.0; 55.7; 89.0 Percentage of area with sharp sensation
Healthy
Primary: Area Under the Concentration-time Curve of BI 409306 and Stable Labelled Isotope BI 409306 (C-13/N-15) Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)…